Kevzara
May 25, 2017
Merck’s Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women’s health
Merck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
